People · Operator
Named in public records as an officer, director or promoter · active 2010–2016 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| X-Rx, Inc. | — | Pharmaceuticals | Series A | $8.5M | $263.3M | 2012 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2010 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
Lee Babiss at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lee Babiss on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Thong Le | 2 | 12 |
| Chad Waite | 2 | 11 |
| Noubar Afeyan | 2 | 9 |
| Carl Weissman | 2 | 8 |
| Lindsay Rayle | 2 | 7 |
| Lorence Kim | 2 | 5 |
| Stephane Bancel | 2 | 4 |
| John Mendlein | 2 | 4 |
| PETER HUTT | 2 | 4 |
| Henri Termeer | 2 | 3 |
| Janis Naeve | 2 | 3 |
| Steven Gillis | 1 | 23 |
| Steve Gillis | 1 | 13 |
| David Schubert | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| B. Judd Hartman | 1 | 3 |
| Richard W. Wagner | 1 | 3 |
| Elizabeth Nabel | 1 | 2 |
| Jeffrey W. Troderman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.